Gilead Sciences Statistics
Total Valuation
Gilead Sciences has a market cap or net worth of $140.79 billion. The enterprise value is $157.03 billion.
| Market Cap | 140.79B |
| Enterprise Value | 157.03B |
Important Dates
The next confirmed earnings date is Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | Jun 13, 2025 |
Share Statistics
Gilead Sciences has 1.24 billion shares outstanding. The number of shares has increased by 0.28% in one year.
| Current Share Class | 1.24B |
| Shares Outstanding | 1.24B |
| Shares Change (YoY) | +0.28% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.10% |
| Owned by Institutions (%) | 87.78% |
| Float | 1.24B |
Valuation Ratios
The trailing PE ratio is 23.92 and the forward PE ratio is 13.91. Gilead Sciences's PEG ratio is 0.65.
| PE Ratio | 23.92 |
| Forward PE | 13.91 |
| PS Ratio | 4.91 |
| Forward PS | 4.78 |
| PB Ratio | 7.35 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.30 |
| P/OCF Ratio | 13.58 |
| PEG Ratio | 0.65 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.44, with an EV/FCF ratio of 15.95.
| EV / Earnings | 26.33 |
| EV / Sales | 5.46 |
| EV / EBITDA | 11.44 |
| EV / EBIT | 14.34 |
| EV / FCF | 15.95 |
Financial Position
The company has a current ratio of 1.37, with a Debt / Equity ratio of 1.31.
| Current Ratio | 1.37 |
| Quick Ratio | 1.06 |
| Debt / Equity | 1.31 |
| Debt / EBITDA | 1.80 |
| Debt / FCF | 2.53 |
| Interest Coverage | 11.14 |
Financial Efficiency
Return on equity (ROE) is 32.66% and return on invested capital (ROIC) is 15.79%.
| Return on Equity (ROE) | 32.66% |
| Return on Assets (ROA) | 12.14% |
| Return on Invested Capital (ROIC) | 15.79% |
| Return on Capital Employed (ROCE) | 24.84% |
| Revenue Per Employee | $1.63M |
| Profits Per Employee | $338,920 |
| Employee Count | 17,600 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 3.45 |
Taxes
In the past 12 months, Gilead Sciences has paid $860.00 million in taxes.
| Income Tax | 860.00M |
| Effective Tax Rate | 12.60% |
Stock Price Statistics
The stock price has increased by +48.80% in the last 52 weeks. The beta is 0.35, so Gilead Sciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | +48.80% |
| 50-Day Moving Average | 110.42 |
| 200-Day Moving Average | 101.81 |
| Relative Strength Index (RSI) | 53.95 |
| Average Volume (20 Days) | 5,536,026 |
Short Selling Information
The latest short interest is 22.54 million, so 1.81% of the outstanding shares have been sold short.
| Short Interest | 22.54M |
| Short Previous Month | 20.99M |
| Short % of Shares Out | 1.81% |
| Short % of Float | 1.82% |
| Short Ratio (days to cover) | 2.80 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of $28.74 billion and earned $5.97 billion in profits. Earnings per share was $4.73.
| Revenue | 28.74B |
| Gross Profit | 22.50B |
| Operating Income | 10.95B |
| Pretax Income | n/a |
| Net Income | 5.97B |
| EBITDA | 13.72B |
| EBIT | 10.95B |
| Earnings Per Share (EPS) | $4.73 |
Balance Sheet
The company has $8.71 billion in cash and $24.95 billion in debt, giving a net cash position of -$16.24 billion or -$13.06 per share.
| Cash & Cash Equivalents | 8.71B |
| Total Debt | 24.95B |
| Net Cash | -16.24B |
| Net Cash Per Share | -$13.06 |
| Equity (Book Value) | 19.08B |
| Book Value Per Share | 15.39 |
| Working Capital | 4.56B |
Cash Flow
In the last 12 months, operating cash flow was $10.37 billion and capital expenditures -$522.00 million, giving a free cash flow of $9.84 billion.
| Operating Cash Flow | 10.37B |
| Capital Expenditures | -522.00M |
| Free Cash Flow | 9.84B |
| FCF Per Share | $7.91 |
Margins
Gross margin is 78.29%, with operating and profit margins of 38.11% and 20.76%.
| Gross Margin | 78.29% |
| Operating Margin | 38.11% |
| Pretax Margin | 23.75% |
| Profit Margin | 20.76% |
| EBITDA Margin | 47.76% |
| EBIT Margin | 38.11% |
| FCF Margin | 34.26% |
Dividends & Yields
This stock pays an annual dividend of $3.16, which amounts to a dividend yield of 2.81%.
| Dividend Per Share | $3.16 |
| Dividend Yield | 2.81% |
| Dividend Growth (YoY) | 2.63% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 65.95% |
| Buyback Yield | -0.28% |
| Shareholder Yield | 2.51% |
| Earnings Yield | 4.24% |
| FCF Yield | 6.99% |
Analyst Forecast
The average price target for Gilead Sciences is $111.91, which is -1.12% lower than the current price. The consensus rating is "Buy".
| Price Target | $111.91 |
| Price Target Difference | -1.12% |
| Analyst Consensus | Buy |
| Analyst Count | 24 |
| Revenue Growth Forecast (5Y) | 3.67% |
| EPS Growth Forecast (5Y) | 94.39% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on January 28, 2013. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 28, 2013 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Gilead Sciences has an Altman Z-Score of 3.19 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.19 |
| Piotroski F-Score | 7 |